OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	203
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	151
Steroid tapering after GVHD Rx: not too fast, not too slow	139
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	138
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	131
Addressing and overcoming disparities in GVHD	121
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	119
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	117
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	115
On a collision course: SARS-CoV-2 variants and CAR T cells	105
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	102
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	102
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	101
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	97
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	97
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	95
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	91
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	91
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	89
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	89
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	87
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	86
Best but not perfect: indirect measure of low iron stores	86
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	85
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	84

COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	81
Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis	78
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	78
Targeting bone marrow mesenchymal stromal cells-derived IL-6 to overcome acute myeloid leukemia chemoresistance	77
Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenström macroglobulinemia: A pooled analysis	77
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	76
Applying CRISPR-Cas9 screens to dissect hematological malignancies	75
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	73
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in lymphoma patients	69
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	67
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	66
Genome-wide whole-blood transcriptome profiling across inherited bone marrow failure subtypes	65
Transfusion therapy for sickle cell disease: what’s new?	65
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model	65
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	63
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	63
Complement C5 inhibition in early onset HELLP syndrome	63
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	63
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	62
Priapism Before and After Hematopoietic Stem Cell Therapy in Individuals with Sickle Cell Disease	61
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	61
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	61
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	60
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	60
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	59
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	59
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial	59
CD58 loss in tumor cells confers functional impairment of CAR T cells	57
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	57
Bite-size introduction to canine hematologic malignancies	57
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	57
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	57